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Patients with chronic kidney disease (CKD) have high
mortality following myocardial infarction (MI), but are less
likely to undergo coronary angiography than those without
CKD. Whether this phenomenon is explained by differences
in the presentation of MI or by bias against performing
coronary angiography in patients with CKD is unclear. We
examined the clinical presentation of 1876 elderly patients
who presented with MI and categorized them by estimated
glomerular filtration rate: 460 ml/min (no/mild CKD),
30–60 ml/min (CKD Stage 3) or o30 ml/min (CKD Stage 4/5).
Compared with patients with no/mild CKD, patients with CKD
Stage 3 or Stage 4/5 had more comorbidity, greater prior
nursing home use, and higher frequency of conduction
abnormalities or anterior infarction. By contrast, peak
creatinine kinase-MB fraction (CK-MB) concentrations were
lower and ST-elevation MI was less common in patients with
CKD Stage 3 or Stage 4/5. In univariate analyses, patients
with CKD Stage 4/5 (odds ratio (OR)¼ 0.34, 95% confidence
interval (CI): 0.23–0.50) or Stage 3 (OR¼ 0.57, 95% CI:
0.45–0.73) were markedly less likely to undergo angiography
than subjects with no/mild CKD. After multivariable
adjustment, the association of CKD Stage 3 with the use of
coronary angiography was attenuated (OR¼ 0.78, 95% CI:
0.60–1.03), but CKD Stage 4/5 remained strongly associated
with lower use (OR¼ 0.52, 95% CI: 0.34–0.80). Clinical features
of MI are different in patients with and without CKD and may
partly explain the low use of angiography in patients with
CKD Stage 3. However, the clinical features of MI do not
account for its underuse in MI patients with CKD Stages 4/5.
Whether reduced use of angiography in patients with
advanced CKD is justified must be evaluated in formal
risk-benefit analyses.
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The relationship between chronic kidney disease (CKD) and
cardiovascular disease has drawn increasing attention in
recent years. The importance of kidney function as a risk
factor for cardiovascular events and the survival after such an
event is well-established.1,2 The contributions of oxidative
stress and inflammation in the etiology of cardiovascular
disease in patients with CKD have been the focus of
numerous studies,3 but less attention has been paid to the
potential contribution of underuse of standard cardiovascu-
lar therapies in patients with CKD.2,4–6
Current guidelines recommend that patients with acute
myocardial infarction (MI) receive aspirin, statins, beta
blockers, angiotensin converting enzyme inhibitors, and early
coronary intervention,7 but patients with CKD are less likely
than patients with normal renal function to receive these
medications or to undergo coronary angiography following
an MI.2,5,6,8 Explanations for the reduced utilization of
potentially life-saving therapies in this high-risk population
remain obscure. As reduced rates of use of these potentially
life-saving interventions are found even in patients who meet
standard indications for medical and interventional thera-
pies,5,6 some authors have suggested that ‘renalism’6 –
therapeutic nihilism toward patients with CKD – is
responsible and have argued that reduced use of standard
therapies in patients with CKD and MI may partly account
for their increased mortality.
An alternative explanation for current practices is that MI
presents differently in patients with and without CKD and
that these differences drive the reduced use of medical
therapies and coronary interventions in patients with CKD.
Understanding whether MI presents differently in patients
with CKD and how these putative differences in presentation
may relate to clinical decision making are critical steps in
the formulation of any plans to increase procedure and
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medication use after MI in patients with CKD. To date,
neither the differences in the presentation of MI among
patients with varying degrees of renal insufficiency nor the
influence of specific clinical features on the use of coronary
angiography have been well characterized. In this study, we
sought to identify whether differences in the presentation of
MI in elderly patients differed by degree of renal function and
to evaluate the role of difference in presentation in the use of
coronary angiography following MI.
RESULTS
Baseline characteristics
Among the 2103 patients admitted for MI during the study
period, 1876 patients had sufficient data to calculate the
baseline estimated glomerular filtration rate (eGFR). Of these,
326 (17.9%) had an eGFRo30 ml/min (CKD Stage 4/5; 24 of
these had evidence of prior dialysis treatment), 943 (51.8%)
had an eGFR between 30 and 60 ml/min (CKD Stage 3), and
607 (33.2%) had an eGFR of Z60 ml/min (either no CKD or
CKD Stage 1/2; we will use ‘no/mild CKD’ from here on).
Patients with CKD Stage 3 or CKD Stage 4/5 were older than
those with no/mild CKD (82.2 and 82.1 vs 79.5 years old,
Ptrendo0.001; Table 1), and they were much more likely to have
been admitted to a nursing home in the previous year (19.6
and 13.5% vs 10.2%, Ptrendo0.001). They also were more likely
than those with normal renal function to have diabetes,
hypertension, congestive heart failure, peripheral vascular
disease, prior stroke, prior MI, or a history of angioplasty or
coronary artery bypass surgery than patients with no/mild
CKD. Patients with CKD were also less likely to be smokers
(Table 1).
Medication use also varied with baseline kidney function.
The overall number of medications prescribed during the
previous year tended to increase with lower eGFR. Patients
with CKD Stages 3 or Stage 4/5 were more likely to be using
angiotensin converting enzyme inhibitors or angiotensin-
receptor blockers (46.9 and 42.4 vs 36.2%, Ptrend¼ 0.004),
diuretics (16.0 and 11.8% vs 6.4%, Ptrendo0.001), and
nitrates (52.8 and 47.5 vs 39.5%, Ptrendo0.001). Conversely,
those with CKD Stage 3 or Stage 4/5 were less likely to have
used aspirin during the 48 h before admission (7.7 and 12.8
vs 15.0%, Ptrend¼ 0.005). Other baseline characteristics of the
cohort are summarized in Table 1.
Clinical and laboratory presentation of MI
There were no significant differences by eGFR class in the time
of admission (Table 2). ST-elevation MI was less frequent in
patients with CKD Stage 3 or Stage 4/5 (10.0 and 8.3 vs 13.5%,
Ptrend¼ 0.01), but patients with CKD were more likely to
develop new electrocardiogram (EKG) abnormalities after
admission. In particular, patients with CKD Stage 3 or Stage 4/
5 were more likely than patients without significant CKD to
develop left bundle branch block (12.5 and 16.2 vs 8.9%,
Ptrendo0.001) or second and third degree heart block (3.6 and
5.9 vs 2.7%, Ptrend¼ 0.02). Peak creatinine phosphokinase and
Troponin I did not vary with renal function, however,
creatinine kinase-MB fraction (CK-MB) concentration was
significantly lower in patients with CKD Stage 3 or Stage 4/5
than in patients with no/mild CKD (52.0 and 56.6 U/l vs
75.5 U/l, Ptrend¼ 0.002). Clinical and electrocardiographic
characteristics of MI are summarized in Table 2.
Procedure use and association of clinical presentation
with receipt of angiography
Cardiac procedure use was inversely related to baseline kidney
function. As shown in Figure 1, there was a significant,
declining trend by increasing CKD stratum to undergo
diagnostic angiography, percutaneous coronary intervention,
or coronary artery bypass surgery. From univariate analyses
(Table 3), patients with CKD Stage 4/5 were one-third as likely
as subjects with no/mild CKD to undergo coronary angio-
graphy (odds ratio (OR)¼ 0.34, 95% confidence interval (CI):
0.23–0.50), whereas patients with CKD Stage 3 were 43% less
likely (OR¼ 0.57, 95% CI: 0.45–0.73).
Among baseline variables, increasing age (OR¼ 0.91, 95%
CI: 0.89–0.93), admission from a nursing home (OR¼ 0.40,
95% CI: 0.26–0.62), having spent more days in the hospital
during the preceding year (OR¼ 0.98, 95% CI: 0.97–1.00),
greater number of medications prescribed in the previous
year (OR¼ 0.97, 95% CI: 0.96–0.99), prior congestive heart
failure (OR¼ 0.46, 95%CI: 0.36–0.59), history of dementia
(OR¼ 0.24, 95% CI: 0.13–0.45), history of bleeding
(OR¼ 0.46, 95% CI: 0.30–0.69), and nitrate use (OR 0.62,
95% CI: 0.49–0.78) were strong negative predictors of the use
of diagnostic or interventional angiography. MI characteristics
were also related to the use of angiography. Patients with
antero-septal MI (OR¼ 0.33, 95% CI: 0.17–0.64) and patients
with left bundle branch block (OR¼ 0.46, 95% CI: 0.29–0.72)
were less likely to undergo angiography, whereas patients with
posterior infarctions were nearly twice as likely as others to
undergo angiography (OR¼ 1.89, 95% CI: 1.43–2.50).
Adjustment for comorbid conditions and clinical pre-
sentation attenuated the negative association of renal
insufficiency with post-infarction use of coronary angiogra-
phy. In multivariable analyses (Table 3), the association
between CKD Stage 3 (vs no/mild CKD) and the likelihood
of angiography was no longer significant (OR¼ 0.78, 95%
CI: 0.60–1.03), whereas CKD Stage 4/5 (OR¼ 0.52, 95% CI:
0.34–0.80) remained independently associated with lower use
of angiography. History of congestive heart failure, dementia,
bleeding, and presence of right bundle branch block were also
negatively associated with the likelihood of undergoing
coronary angiography in multivariate analyses (Table 3).
Conversely, history of previous percutaneous coronary
intervention (OR¼ 1.69, 95% CI: 1.15–2.47) and presenta-
tion with posterior infarction (OR¼ 2.10, 95% CI: 1.59–2.77)
were strongly associated with the use of angiography.
DISCUSSION
Patients with CKD have a 38–70% increase in the risk of
death following admission for MI,2 but they nevertheless
undergo coronary angiography less frequently than those
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without significant impairment of renal function.6 To better
understand the reasons behind the reduced use of this
potentially life-saving procedure, we studied 1876 elderly
patients who were hospitalized with acute MI, and found that
baseline medical conditions, MI location, electrocardio-
graphic findings, and cardiac enzymes during presentation
of MI were substantially different in patients with moderate
or advanced CKD compared with those with preserved renal
function. We found, furthermore, that these differences
substantially confounded the relationship between kidney
function and the use of diagnostic angiography. After
adjustment, the odds of undergoing diagnostic angiography
increased in patients with CKD Stage 4/5 and were no longer
significantly different in subjects with Stage 3 CKD compared
with those with more normal renal function.
Few prior studies have analyzed how kidney function
impacts the presentation of MI. Sosnov et al.9 recently
examined 4482 patients who were hospitalized with MI in
Worcester, MA and found that patients with GFR ofo60 ml/
min were less likely have chest, arm, neck, or shoulder pain
and more likely to be short of breath than subjects with
normal GFR. Other studies analyzing MI symptoms in
subjects with CKD are lacking, but ST elevation,10–12 and Q-
wave infarction9,10 seem to be less frequent in patients with
CKD than in subjects without CKD. In contrast, MI location
has not been consistently related to renal function.9–12
In this study, we also found a lower frequency of ST-
elevation MI in patients with CKD Stage 3 or Stage 4/5 than
in those with no/mild CKD, but in contrast to previous
studies found that the rate of Q-wave MI was not
significantly different and that the rate of anterior infarction
markedly increased as renal function declined. This study
extends upon previous observations by demonstrating that
despite the lower frequency of ST-elevation MI, electro-
cardiographic abnormalities such as high-grade heart block,
bundle branch block, and atrial fibrillation were more
common in patients with CKD. It is possible that this
increased incidence of conduction abnormalities is related to
a greater frequency of prior MI or electrolyte abnormalities,
or more left ventricular hypertrophy in the patients with
CKD, but further studies are needed to confirm this
hypothesis.
Table 1 | Baseline characteristics of study population (N=1876)
Variable
eGFR
Count (%) or mean (7s.d.) o30 (N=326) 30–60 (N=943) 460 (N=607) P-value for trend
Age (years) 82.1 (77.0) 82.2 (76.5) 79.5 (76.6) o0.001
Male sex 67 (20.6) 162 (17.2) 146 (24.1) 0.06
Race
White 308 (94.5) 897 (95.1) 569 (93.7) 0.32
Black 11 (3.4) 28 (3.0) 28 (4.6)
Other 7 (2.2) 18 (1.9) 10 (1.7)
Nursing home admission in previous year 64 (19.6) 127 (13.5) 62 (10.2) o0.001
Inpatient days in previous year 9.5 (16.8) 6.1 (11.7) 4.3 (9.6) o0.001
Admitted from nursing home 42 (12.9) 92 (9.8) 39 (6.4) o0.001
Current smoking 27 (8.3) 90 (9.5) 82 (13.5) 0.006
Previous MI 143 (43.9) 367 (38.9) 207 (34.1) 0.003
Prior CABG 58 (17.8) 141 (15.0) 71 (11.7) 0.009
Prior angioplasty 21 (6.4) 87 (9.2) 70 (11.5) 0.01
Prior stroke 75 (23.1) 212 (22.5) 103 (17.0) 0.01
Diabetes 149 (45.7) 374 (39.7) 204 (33.6) o0.001
Hypertension 269 (82.5) 764 (81.0) 447 (73.6) o0.001
Congestive heart failure 205 (62.9) 422 (44.8) 184 (30.3) o0.001
COPD 87 (26.7) 238 (25.2) 179 (29.5) 0.21
Dementia 42 (12.9) 103 (10.9) 40 (6.6) o0.001
Peripheral vascular disease 96 (29.5) 279 (29.6) 146 (24.1) 0.04
Peptic ulcer disease 64 (19.6) 132 (14.0) 100 (16.5) 0.44
History of GI bleeding 59 (18.1) 117 (12.4) 78 (12.9) 0.06
Medications
Acetylsalicylic acida 25 (7.7) 121 (12.8) 91 (15.0) 0.005
ACEI/ARB 153 (46.9) 400 (42.4) 220 (36.2) 0.005
Beta blocker 92 (28.2) 263 (27.9) 160 (26.4) 0.49
Calcium channel blocker 164 (50.3) 404 (42.8) 246 (40.5) 0.007
Statin 83 (25.5) 205 (21.7) 128 (21.1) 0.16
Nitrates 172 (52.8) 448 (47.5) 240 (39.5) o0.001
Diuretics 49 (15.0) 111 (11.8) 39 (6.4) o0.001
Total number of medications prescribed in previous year 13.0 (77.6) 11.2 (77.2) 10.8 (77.0) o0.001
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; GI, gastrointestinal; MI, myocardial infarction.
aWithin 48 h before arrival (from Medical Record Review).
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An additional, unique observation of the current study is
that peak CK-MB levels were markedly lower in patients with
CKD Stage 3 or Stage 4/5 than in those with more preserved
renal function. This may reflect lesser degrees of myocardial
necrosis and damage, perhaps related to the lower rate of ST-
elevation infarction. Alternatively, levels of necrosis may be
similar with a delayed presentation in subjects with moderate
or advanced CKD accounting for the lower peak CK-MB
levels. The observed similarity in peak Troponin levels
supports this hypothesis, but it may have been influenced
by differential metabolism in subjects with and without
CKD.13 Further exploration of this hypothesis in a cohort
with data on the interval between symptom onset and
hospital arrival, or scintigraphic assessment of infarct size is
warranted.
Although previous studies have indicated that use of
angiography may be lower in patients with advanced kidney
disease, our study clearly demonstrates the extent of the
confounding that is present in unadjusted comparisons.
Specifically, although a direct association between kidney
function and angiography use can still be shown in carefully
adjusted analyses, the relative magnitude of underuse is
markedly reduced after adjustment for numerous baseline
characteristics, such as detailed measures of comorbidity,
Table 2 | Clinical features of myocardial infarction (N=1876)
Variable
eGFR
Count (%) or mean (7s.d.) o30 30–60 460 P-value for trend
MI present on arrival to hospital 308 (97.5) 902 (97.5) 578 (97.3) 0.85
Arrival time of day (hhmm)
0001–0600 36 (11.3) 151 (16.5) 100 (16.7)
0601–1200 120 (37.7) 342 (37.4) 217 (30.2)
1201–1800 103 (32.4) 246 (26.9) 181 (36.2)
1801–2400 59 (18.6) 176 (19.2) 102 (17.0) 0.15
Admission EKG
Q-waves 26 (8.6) 78 (9.0) 32 (5.8) 0.07
ST elevation 25 (8.3) 87 (10.0) 75 (13.5) 0.01
Left bundle branch block 33 (10.9) 81 (9.3) 40 (7.2) 0.06
Second or third degree heart block 6 (2.0) 12 (1.4) 8 (1.4) 0.61
MI location
Antero-septal 52 (16.0) 95 (10.1) 41(6.8) o0.001
Lateral 96 (29.5) 305 (32.3) 215 (35.4) 0.06
Inferior 12 (3.7) 57 (6.0) 36 (5.9) 0.221
Posterior 64 (19.6) 187 (19.8) 136 (22.4) 0.25
EKG findings before discharge
Atrial fibrillation 91 (28.3) 226 (24.2) 122 (20.3) 0.005
Ventricular fibrillation or tachycardia 1 (0.3) 3 (0.3) 4 (0.7) 0.36
Left bundle branch block 52 (16.2) 117 (12.5) 53 (8.9) o0.001
Right bundle branch block 55 (17.1) 108 (11.5) 53 (8.8) o0.001
Fasicular blocks 51 (15.8) 153 (16.4) 92 (15.3) 0.74
Second or third degree heart block 19 (5.9) 34 (3.6) 16 (2.7) 0.02
Laboratory findings
Hemoglobin (g/dl) 11.3 (72.0) 12.4 (71.9) 12.9 (71.8) o0.001
Creatinine (mg/dl) 2.9 (71.5) 1.3 (70.3) 0.9 (70.2) o0.001
Peak CPK (U/l) 537 (7801) 591 (7916) 620 (7926) 0.22
Median (IQR) 279 (127–591) 293 (138–646) 287 (119–714)
Peak CK-MB (U/l) 52.0 (7101.8) 56.6 (793.3) 75.5 (7134.3) 0.002
Median (IQR) 21.7 (8.5–50.6) 19.7 (8.8–59.1) 23.0 (8.2–81.5)
Peak Troponin I (U/l) 38.9 (7102.1) 40.4 (7112.9) 38.9 (7133.2) 0.97
Median (IQR) 10.9 (1.6–38.9) 6.0 (1.3–24.3) 6.6 (1.6–23.9)








































Figure 1 | Rates of coronary interventions by category of eGFR.
CABG – coronary artery bypass graft; eGFR – estimated glomerular
filtration rate, in ml/min/1.73 m2. P-values are for trend across
categories.
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previous admission to a nursing home, electrocardiographic
findings, and laboratory features of MI. These findings are
consistent with our previous work on the differential use of
cardiovascular medications following MI in subjects with
CKD compared with those without CKD.14 Previous studies
have suggested that angiography is used less frequently after
MI in subjects with CKD,2,6 but explanations for this
phenomenon have been lacking. On the basis of their finding
that angiography was used less frequently in subjects with
CKD even when standardized criteria suggested that
angiography was appropriate, others have proposed that
therapeutic nihilism toward patients with CKD might be
responsible.6 Our study provides a broader and more
complete picture of the differential use of angiography in
patients with moderate or advanced CKD and the role of
therapeutic nihilism in this process. Therapeutic nihilism is
likely to play an important role in the 22–48% difference in
the likelihood of angiography that remains after adjustment
Table 3 | Associations with receipt of angiography after admission for myocardial infarction
Characteristic
Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
Age (per year) 0.91 0.89–0.93 o0.001 0.93 0.91–0.95 o0.001
Male gender 0.81 0.60–1.09 o0.16 0.70 0.50–0.96 0.03
Race
White Referent — — Referent — —
Black 1.82 1.06–3.10 0.03 1.72 0.96–3.10 0.06
Other 0.88 0.36–2.14 0.78 0.80 0.31–2.05 0.64
eGFR (ml/min)
Z60 Referent — Referent — —
30–60 0.57 0.45–0.73 o0.001 0.78 0.60–1.03 0.08
o30 0.34 0.23–0.50 o0.001 0.52 0.34–0.80 0.003
Prior nursing home stay 0.40 0.26–0.62 o0.001 0.58 0.36–0.92 0.02
Hospital days in prior year (per day) 0.98 0.97–1.00 0.008
Prior CABG 1.29 0.95–1.76 0.11 1.20 0.85–1.71 0.31
Prior PTCA 1.96 1.39–2.76 o0.001 1.69 1.15–2.47 0.007
Prior stroke 0.73 0.54–0.98 0.04 — — —
Prior CHF 0.46 0.36–0.59 o0.001 0.60 0.45–0.78 o0.001
Dementia 0.24 0.13–0.45 o0.001 0.36 0.19–0.69 0.002
Peptic ulcer disease 0.78 0.56–1.08 0.14 — — —
History of bleeding 0.46 0.30–0.69 o0.001 0.53 0.34–0.83 0.005
Peripheral vascular disease 0.76 0.58–0.99 0.04 — — —
History of diabetes 1.08 0.85–1.36 0.52 — — —
Number of different drugs in prior year (per medication) 0.97 0.96–0.99 0.005 — — —
Medication use before MI
Aspirin 1.93 1.42–2.62 o0.001 — — —
Statin 1.37 1.05–1.78 0.02 — — —
Nitrates 0.62 0.49–0.78 o0.001 — — —
Diuretics 0.63 0.41–0.96 0.03 — — —
Location of MI (each vs all other)
Antero-septal 0.33 0.17–0.64 o0.001 — — —
Lateral 0.99 0.76–1.29 0.93 — — —
Posterior 1.89 1.43–2.50 o0.001 2.10 1.59–2.77 o0.001
Inferior 1.56 0.99–2.46 0.06 — — —
Arrival time during night (0600–1800 hours) 0.72 0.56–0.93 0.01 — — —
Electrocardiogram findings at arrival
Left bundle branch block 0.46 0.29–0.72 o0.001 0.59 0.36–0.96 0.03
Right bundle branch block 0.40 0.22–0.71 0.002 0.43 0.24–0.80 0.007
Fascicular block 0.51 0.31–0.86 0.02 — — —
Q-waves 0.62 0.37–1.03 0.06 0.61 0.35–1.05 0.07
ST elevation 1.37 0.96–1.95 0.09 1.07 0.72–1.58 0.73
Laboratory values
Hemoglobin (per 1 g/dl) 1.06 0.99–1.12 0.07 1.23 1.06–1.42 0.005
Peak CK-MB (per 100 U/l) 1.36 1.23–1.52 o0.001 1.09 0.97–1.23 0.16
Peak Troponin (per 100 U/l) 1.16 1.06–1.27 0.002 0.93 0.85–1.01 0.12
CABG, coronary artery bypass graft; CHF, congestive heart failure; CI, confidence interval; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MI, myocardial
infarction; OR, odds ratio; PTCA, percutaneous transluminal coronary angioplasty.
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for clinical presentation, but our results suggest that
differences in clinical presentation of MI and patient
characteristics are equally important in explaining the low
rate of angiography in patients with moderate and advanced
CKD.
The apparent discrepancy between our findings and
previous studies has several explanations. First, our results
suggest that prior nursing home stay, congestive heart failure,
dementia, history of bleeding, MI location, and EKG findings
are strongly associated with the use of angiography and
should be adjusted for when analyzing procedure use in
patients with CKD. Second, indications for the use of
angiography have considerably broadened in the decade, as
the patients in the prior study6 were admitted and
appropriateness criteria used were developed.15 These
changes or a greater awareness of the risk associated with
moderate and advanced CKD may have lessened the role of
bias against the use of coronary angiography in patients with
CKD in recent years. Finally, the use of a dichotomous
definition of renal function6 may mask important differences
in the way patients with moderate and advanced CKD
are treated after MI. We used three categories of eGFR and
found that the strength of the association of CKD with the
use of angiography was proportional to the severity of renal
disease. Although clinical presentation largely explained the
low use in subjects with moderate CKD, our estimates of the
adjusted relative risk of undergoing angiography in subjects
with advanced CKD (OR¼ 0.52) were similar to those of
previous authors.6
Our findings suggest that clinical factors play a significant
role in the decision not to perform angiography in patients
with renal disease. Therapeutic nihilism is likely to play an
important role, but its effect is less prominent than
unadjusted procedure rates suggest and appears to be
prominent only in patients with advanced renal disease. It
is unclear whether withholding angiography after MI in
patients with advanced CKD is justified given the lack of
evidence on its efficacy or safety in this specific group of
patients. Retrospective studies suggest that the use of
angiography after MI is associated with markedly lower
mortality rates in patients with CKD,6 but evidence from
prospective, randomized studies is lacking due to the
exclusion of patients with CKD from interventional trials.
Within the stratum of patients with advanced CKD, concerns
about the possibility of contrast nephropathy, cholesterol
embolism, and patient attitudes about the relative merits of
freedom from dialysis and overall lifespan may play
legitimate roles in the decision to proceed with or without
diagnostic angiography. Randomized trials in the CKD
population are sorely needed, as are studies to determine
the quality of life and relative risks of death and end-stage
renal disease after diagnostic angiography in patients with
advanced CKD.
Our study has several limitations. First, our cohort was
restricted to seniors and included a high percentage
of women. Second, our population had a low frequency of
ST-elevation MI across all three GFR categories. This low
relative frequency of ST-elevation vs non-ST MI is similar to
that seen in other studies of women and the elderly,16,17 but
our results may not be generalizable to younger, predomi-
nantly male cohorts with MI. Third, the use of the admission
creatinine to estimate GFR may have resulted in occasional
misclassification of GFR and CKD status, because we were
unable to standardize the measured creatinine against the
Cleveland Clinic laboratory and because the admission
creatinine may not uniformly correlate with the stable
outpatient creatinine before MI admission. However, we
have previously demonstrated within this data set that GFR
estimates using the admission creatinine are well correlated
with the use of CKD codes in the year before admission.18
Further, given the large number of patients and centers,
deviations from the Cleveland Clinic creatinine or from the
stable outpatient creatinine are likely to have affected patients
with and without CKD non-differentially and are unlikely
to have more than minimal influence on the nature of our
findings. Finally, the retrospective nature of our study
precluded analysis of several factors that could play
important roles in the use of angiography. We were not able
to assess for differences in features of MI, such as delay in
presentation after the onset of symptoms, ejection fraction,
Killip class, presentation in cardiovascular shock, hospital
course, or patient preference. Residual confounding by these
and other features as well as a lack of power to detect small
associations cannot be excluded in the current multivariate
analysis and merit further study.
Similarly, our study does not address whether the
differential use of coronary angiography that we observed is
clinically appropriate. We did not address appropriateness in
the current study for several reasons. Our study was
motivated by prior work indicating that both medical and
interventional cardiovascular therapies are routinely withheld
from patients with significant CKD regardless of whether
standard indications for the use of those therapies are
present.5,6 Significant correction of this underutilization of
cardiovascular therapies is unlikely without a better under-
standing of why cardiovascular therapies are utilized less
frequently in patients with CKD. In other words, under-
standing how MI presentation is altered by the presence of
CKD as well how differences in MI presentation modify the
association of CKD with the utilization of coronary
angiography is likely to provide information that is clinically
significant and independently important of the question of
appropriateness.
In addition, criteria for the use of coronary angiography
are in constant flux, have evolved considerably in recent
years, and currently require very detailed clinical informa-
tion compared with the guidelines developed only a few years
ago7,15,19,20 that were used in previous studies of this
question. As a result, retrospective studies, such as the
current study, will only rarely have sufficient data to fairly
assess appropriateness. Even where sufficient data exist,
use of these criteria in retrospective studies risks imposing
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anachronistic definitions of appropriateness not in use at the
time of the index admissions. Finally, clinical trials in
cardiology have routinely excluded patients with CKD.21 The
risks and benefits of post-MI angiography in patients with
CKD are therefore uncertain, and whether criteria for
appropriateness can be objectively constructed or fairly
applied to the CKD population is open to debate.
In light of these considerations, we felt that a focus on the
factors influencing the utilization of angiography was a more
correct use for our data than a comparison of appropriate-
ness in patients with vs without CKD. However, prospective
studies of the association of the clinical presentation of MI,
and the appropriateness of clinical decisions on the use of
coronary angiography in patients with CKD would be highly
informative and are clearly warranted by our results.
In summary, we examined the features of MI and the use
of angiography in a contemporary cohort of elderly patients.
We found that the presentation of MI was substantially
different in patients with CKD Stage 3 or Stage 4/5 compared
with those with no/mild CKD. Elderly patients with Stage 3
or even more advanced CKD undergo coronary angiography
after MI less frequently than patients with mild or free from
CKD. Differences in comorbidity and clinical presentation of
MI largely explain the reduced use of angiography in patients
with CKD Stage 3, but do not fully explain the reduced use of
angiography in subjects with more advanced CKD. Further
studies are needed to determine why angiography is withheld
after MI in subjects with CKD and to determine the




We conducted this study using data on 2103 patients who
experienced an MI in Pennsylvania in 1999 and 2000. This data
set has been used to validate claims-based algorithms for the
identification of MI patients or patients with CKD from adminis-
trative data.18,22 The source population included all Medicare
beneficiaries in Pennsylvania who were also enrolled in that state’s
Pharmaceutical Assistance Contract for the Elderly in 1999 and
2000. Pharmaceutical Assistance Contract for the Elderly is a state-
run pharmacy benefits program that provides comprehensive
medication coverage for low and middle-income elderly in that
state. Patients who were hospitalized with an MI were identified by
an ICD-9-CM code of 410.xx (acute MI) as a discharge diagnosis in
the primary or secondary position.
The claims information was used to record each subject’s date of
birth, gender, dates of admission and discharge, and the American
Hospital Association provider number for the treating hospitals.
This information was supplied to a Peer Review Organization, which
then acquired the hospital records for each admission. Trained
hospital records abstractors at the Peer Review Organization
performed hospital chart review using a structured chart abstraction
protocol. Data elements included gender, date of birth, detailed
information relevant to the diagnosis of acute MI, as well as serum
creatinine, cardiac enzymes, medication, and procedure use. The
inter-rater agreement (kappa) of the structured chart abstraction,
for all data elements in a 20-chart sample, was 0.931. The 1876
patients in this initial data set that had sufficient information
to calculate a creatinine clearance served as the final population for
this study.
Main exposure variable: assessment of kidney function
For each patient, we used the first serum creatinine measurement
after admission for MI, as well as age, gender, and race to estimate
the GFR using the abbreviated version of the modification of diet in
renal disease formula:23
eGFR ¼ 186ðserum creatinine level ½in mg=dlÞ
 1:154ðage ½in yearsÞ  0:203
For women and blacks, the product of this equation was multiplied
by a correction factor of 0.742 and 1.21, respectively. We then
categorized all patients into three strata of baseline kidney
function: eGFR X60 (absence of CKD or CKD Stage 1/2; ‘no/mild
CKD’), 30 to o60 (CKD Stage 3), and o30 ml/min/1.73 m2 (CKD
Stage 4/5).
Baseline variables and clinical presentation
We ascertained each patient’s race, gender, and age from the
Pharmaceutical Assistance Contract for the Elderly eligibility files.
Medicare claims from the 365 days before MI admission were used
for to ascertain number of hospitalization days, the number of days
in a nursing home during the year before discharge, and the
presence of peripheral vascular disease and depression. History of
other comorbidities (diabetes, peptic ulcer disease, gastrointestinal
bleeding, dementia, stroke, congestive heart failure, hypertension,
chronic obstructive lung disease, and a history or coronary artery
bypass surgery or percutaneous coronary intervention), time of
admission, electrocardiogram findings, anatomic location of infarc-
tion, and procedure use during the index hospitalization were
determined from structured chart abstraction. Aspirin use during
the 48 h before admission was determined from chart abstraction.
The prior use of prescription cardiovascular drugs within the year
preceding the MI was ascertained from Pharmaceutical Assistance
Contract for the Elderly claims. These claims reflect filled
prescriptions for each patient and include the National Drug Code,
a unique indicator of the specific compound, strength, manufac-
turer, and number of days prescribed. We specifically identified use
of angiotensin converting enzyme inhibitors, angiotensin-receptor
blockers, beta-blockers, calcium-channel blockers, diuretics, nitrates,
and statins in this manner.
Data analysis
The baseline characteristics of the final study cohort were described
according to category of kidney function. Categorical variables were
expressed as count (%) of patients and continuous variables
were expressed as mean7s.d. if normally distributed and addition-
ally as median (interquartile range, IQR) otherwise. Cochrane–-
Mantel–Haenzel tests or univariate analysis of variance was used to
test for significant differences in baseline characteristics according to
CKD class.
Univariate logistic regression was used to test for significant
association with the use of coronary angiography before discharge.
Age, race, sex, and GFR category were forced into multivariate
logistic regression models. Additional variables that had univariate
P-values ofo0.15 were entered into the models and retained only if
their multivariate P-values remained ato0.15. OR and 95% CI were
generated for both univariate and multivariable analyses.
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